RE: Nova decision.....Transition Terminates Novo
small addition repost.....
I see from others statements that The Uninformed are posting again.........LOL!!
Starcan and Polak are Correct.......Transition sent NN Notice terminating the agreement.
Novo and Transition were negotiating for the Exclusive License for The ENTIRE DIABETES Platform A.K.A. an Expanded Agreement.
Transition didn't think that the offer from Novo was good enough and expects to increase the value by moving the platform forward and running Phasell's for TT-223 Stand-Alone as well as TT-223+GLP1. I personally applaud Dr. Cruz & Co. for taking a firm stance with NN. Enough monkeying around here!! It is apparent that Transition upheld their end of the agreement whilst NN dragged their feet with GLP1+TT-223 leading NN to LOSE THAT very promising Therapeutic due to NON-PERFORMANCE. Liraglutide (Novo's GLP1 Analogue STILL not approved ) became their sole focus in the incretin mimetic game. Their loss.
The Uninformed probably will not Recall TT-223 being tested by NN as a Stand Alone in a sand rat model showing a breakthrough Pre-Clinical indication as a hyperglycemic. The implications of this breakthrough pre-clinical will be lost on them as will the ramifications of the model used.
They probably will not Recall, as well, that NN ran a second Phasel dosing TT-223 Alone at doses ranging from 10mg./kg to 30mg./kg in Humans with No adverse Effects AT ALL.
It is probably lost on the Uninformed as well that the Phasella Human Trial proved the Mechanism of Action for TT-223. Proof of Concept was shown in HUMANS! Sustained Efficacy of 6 MONTHS!! Increased Insulin production never before seen in Humans! This trial paralleled the pre-clinicals to the TEE giving further confidence for other Trials with TT-223 ongoing and slated to begin.
So it only goes to show and we can assume that the Uninformed will not understand the reasoning behind the 2 Trials for TT-223 currently ongoing. The SAD TT-223 SA Trial started in Sept. (already without NN)(shame) is now complete and the MAD TT-223 SA Trial is starting. These Trials are being dosed at a rate that will far exceed the 10-30mg./kg previously dosed by Novo in their Trial and by Transition in their Trial. The MAD TT-223 SA Trial will be dosed starting at 30mg./kg and Higher. WHY? What are they looking for?? It is because no-one knows the DLP for TT-223. These trials will establish the DLP for TT-223. What they are looking for is ANY adverse reaction but it is pontificated that HIGH Doses of TT-223 may cause some gastro-intestinal events. "Mommy my tummy hurts." But thats just an educated guess on the Doctors part. So we very well may see some adverse events of that nature because they are trying to find the DLP or we may not. There was no such adverse events of that nature in 2 previous trials dosing up to 30mg./kg.
It is probably lost on the Uninformed as well that TT-223 Stand Alone has Better Results than either Byetta OR Liraglutide did at this stage of the game. Way better when you take into account the Nausea that they both induce in Humans.......whereas TT-223 Does Not.
Manufacturing of TT-223 is ongoing and will be completed soon in preparation for the Phasell TT-223 Stand Alone Trial.
As usual the Uninformed remain just that.....still Uninformed.....LOL!!
Starcon is correct in saying ...."why give it away"....Yup. Agreed.
Now back to the AZD's of Alzheimers and Transitions $200,000,000.00 WorldWide Collaberation Agreement with Elan .